Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
Invest New Drugs 2013;
32:154-9. [PMID:
23609829 PMCID:
PMC3913855 DOI:
10.1007/s10637-013-9964-5]
[Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2013] [Accepted: 03/26/2013] [Indexed: 11/28/2022]
Abstract
Background TAS-106 was designed to inhibit RNA synthesis by blocking RNA polymerases I, II, and III. Methods This was a single-center, open-label, phase I study to identify the maximum tolerated dose (MTD), pharmacokinetics, and biologic effects of the combination of TAS-106 and carboplatin, following a standard 3 + 3 design. This phase I trial was comprised of a regimen of a 60-min IV infusion of carboplatin on day 1 of each 21-day cycle followed by a 24-h infusion of TAS-106, also on day 1 of each cycle. Results 39 patients were treated (21 male, 18 female, median age 62 years, range 21–80 years). Median number of prior therapies was 4. Maximum Tolerated Dose (MTD) was 3 mg/m2 TAS-106 with AU 4 carboplatin. Dose-limiting toxicities were neutropenia and thrombocytopenia, with and without growth factor support. While no patients achieved a complete or partial response, four patients had stable disease lasting ≥4 months, including one patient each with ovarian, non-small cell lung, basal cell and colorectal cancer. Conclusions In summary, the combination of TAS-106 and carboplatin was well-tolerated, and further studies in non-small cell lung and ovarian cancer are warranted to assess the efficacy of this drug combination.
Collapse